InterVenn Biosciences’ Post

• TROP-2 expression in breast cancer is associated with worse survival. • Sacituzumab govitecan, a TROP-2 ADC, improved outcomes in metastatic HR+/HER2-and TNBC regardless of TROP-2 expression. • Datopotamab deruxtecan is another TROP-2 ADC with promising activity in metastatic TNBC. • Future research should include optimizing the side effect profile and identifying predictive biomarkers.

Dr. Rini discusses the background of a biomarker analysis of KEYNOTE-426 in CRC - https://lnkd.in/dbCB8y-G -Brian I. Rini, MD, FASCO, Ingram Professor of Medicine, Department of Medicine, Division of Hematology Oncology, Vanderbilt University; Chief of Clinical Trials, Vanderbilt-Ingram Cancer Center, discusses the background of the pooled analysis of the phase 3 KEYNOTE-426 study (NCT02853331) investigating pembrolizumab (Keytruda) plus axitinib (Inlyta) versus sunitinib (Sutent) for the

Results from the phase 1/1b trial of Inavolisib plus Palbociclib plus Endocrine therapy in PIK3CA mutated HR Pos HER2 negative metastatic breast cancer now published. No Drug Drug Interaction, most common treatment related adverse events were hyperglycemia, stomatitis, diarrhea. The triplet with fulvestrant backbone yielded a mPFS of 35 months. These data formed the basis for the phase 3 INAVO120 trial that has since demonstrated near doubling of mPFS from 7 to 15 months with the addition of Inavolisib compared to fulvestrant and palbociclib in 1L metastatic setting in PIK3CA mutated endocrine resistant disease. Inavolisib now has BTD and priority review by US FDA is expected by Nov 27 2024. Memorial Sloan Kettering Cancer Center Journal of Clinical Oncology

Dr. Rini discusses the background of a biomarker analysis of KEYNOTE-426 in CRC - https://lnkd.in/djA_vg6i -Brian I. Rini, MD, FASCO, Ingram Professor of Medicine, Department of Medicine, Division of Hematology Oncology, Vanderbilt University; Chief of Clinical Trials, Vanderbilt-Ingram Cancer Center, discusses the background of the pooled analysis of the phase 3 KEYNOTE-426 study (NCT02853331) investigating pembrolizumab (Keytruda) plus axitinib (Inlyta) versus sunitinib (Sutent) for the

New molecule developed by #Korea based innovative #biotech TiumBio targeting dual inhibition of transforming growth factor beta receptor 1 (#TGFR1) and vascular endothelial growth factor receptor 2 (#VEGFR2) is rapidly advancing and may bring great news to patients with head and neck squamous cell carcinoma (#HNSCC), biliary tract cancer (#BTC), and colorectal cancer (#CRC). Company just announced dosing of the first patient in Phase 2a trial of #TU2218 in combination with #Keytruda (#Pembrolizumab). https://lnkd.in/eYBip9Je #TU2218 is a first-in-class oral immune-oncology therapy simultaneously targeting transforming growth factor-β (#TGF-β) and vascular endothelial growth factor (#VEGF) that can potentially act to sensitize responses to #PD-1 inhibition in patients. #TU2218 is being investigated as a treatment of solid tumours as a monotherapy (NCT05204862) and in combination with #Keytruda (#Pembrolizumab) (NCT05784688). This rapid movement of the clinical development is a great achievement of the TiumBio oncology team as this very innovative biotech moves pipeline in other areas aside from oncology with most advanced candidate in endometriosis.

Tackling large medical need in microsatellite stable (#MSS) colorectal cancer (#CRC) with improved therapy is persisting challenge. Are we on the verge of breakthrough in immunotherapy option? Possibly and interesting example of strategic navigation in combo therapy development. At #ESMO 2024 #ligufalimab (anti-#CD47 monoclonal antibody) plus #ivonescimab (anti-#VEGF x #PD-1 MAb) combined with chemo yielded ORR of 88% in the first-line CRC patients while chemo plus #ivonescimab alone resulted in an ORR of 82% https://lnkd.in/eVptyQ2w) . This data would argue that in CRC it is likely sufficient to combine #ivonescimab with chemo in order to get to best safety-efficacy profile. No surprise that further development of #ligufalimab in combo with #ivonescimab appears not to be in CRC despite large indication/medical need but in head and neck cancer (#HNSCC) where addition of #ligufalimab doubled ORR when added to #ivonescimab as the new Ph3 trial posted revealed (https://lnkd.in/eWbFe9Jt). Still this is relatively bold move considering small patient sample in the Ph2 but reaching 60% ORR of combo in #PDL-1 positive HNSCC is relatively strong initial signal. #clinical oncology #combination strategy #CRC #HNSCC #Phase3

Astellas Pharma has announced that the #FDA approved #VYLOY (#zolbetuximab-clzb), the first #CLDN18.2-targeted therapy for advanced #gastric and gastroesophageal junction (#GEJ) #cancer. In combination with #chemotherapy, VYLOY improved progression-free and overall survival in patients with HER2-negative, CLDN18.2-positive tumors. This marks a significant advancement in the treatment of CLDN18.2-positive #tumors, a challenging biomarker in #gastriccancer.  https://lnkd.in/dirXvpfT

🚨 Disturbing results 🚨 “Non-small cell lung cancer patients, who should get EGFR-targeted therapies as a frontline option based on biomarker test results and according to the latest treatment guidelines, are receiving immunotherapy instead and are worse off for it”. 🫤 (Turna Ray, Apr 2024, Precision Medicine Online) 💡Our solution: Use Idylla™ FIRST and generate EGFR results in less than 2.5 hours ⏱️! Idylla™ is a fully automated, easy to implement molecular testing platform suitable for any hospital lab setting and enabling rapid in-house biomarker testing ⚡   👀 Check out why you should use Idylla™ first: https://lnkd.in/enNpBhir 👉 Read the full Precision Medicine Online article: https://lnkd.in/eyTWN3Nd

The hottest cancer technology from the turn of the century is finally getting its glow-up moment: antibody-drug conjugates (ADCs) have been outperforming other available drugs across a range of indications, overturning decades of standards of care, and spurring pharma companies to spend $50 billion to snap up their share of the market. Read my latest article in AJMC - The American Journal of Managed Care to learn what this might mean for patients and the broader healthcare industry: https://bit.ly/4c4tUf3 #cancer #oncology #ADCs #pharma #biotech #cancerresearch

🚨 𝐍𝐞𝐰 𝐃𝐚𝐭𝐚 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬 𝐭𝐡𝐞 𝐏𝐨𝐰𝐞𝐫 𝐨𝐟 𝐂𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐆𝐞𝐧𝐨𝐦𝐢𝐜 𝐏𝐫𝐨𝐟𝐢𝐥𝐢𝐧𝐠 (𝐂𝐆𝐏) 𝐢𝐧 𝐂𝐚𝐧𝐜𝐞𝐫 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭! 🚨 A real-world meta-analysis, presented at #ESMO2024, pooled data from 144 studies and revealed groundbreaking insights into CGP's impact on patient outcomes: 🔬 59.8% of patients with metastatic solid tumors had actionable mutations identified through CGP. 🎯 15.6% of these patients received targeted therapies based on CGP results. 📈 The result? Improved survival rates compared to conventional treatments! This data underscores the critical role CGP plays in guiding personalized, targeted cancer therapies, allowing oncologists to tailor treatments to each patient's unique tumor profile. Read more here: https://lnkd.in/dWrtiwUZ #Oncology #GenomicProfiling #PrecisionMedicine #CancerResearch #TargetedTherapy #ESMO